2021
Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts
Akintoye E, Afonso L, Jayanna M, Bao W, Briasoulis A, Robinson J. Prognostic Utility of Risk Enhancers and Coronary Artery Calcium Score Recommended in the 2018 ACC/AHA Multisociety Cholesterol Treatment Guidelines Over the Pooled Cohort Equation: Insights From 3 Large Prospective Cohorts. Journal Of The American Heart Association 2021, 10: e019589. PMID: 34092110, PMCID: PMC8477885, DOI: 10.1161/jaha.120.019589.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmerican Heart AssociationBiomarkersCardiovascular DiseasesCholesterolClinical Decision-MakingCoronary Artery DiseaseDecision Support TechniquesDyslipidemiasFemaleHeart Disease Risk FactorsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedPractice Guidelines as TopicPredictive Value of TestsPrimary PreventionPrognosisRisk AssessmentTime FactorsUnited StatesVascular CalcificationConceptsPooled Cohort EquationsCoronary artery calcium scoreCholesterol treatment guidelinesArtery calcium scoreAtherosclerotic cardiovascular diseaseCohort EquationsRisk enhancersCalcium scoreTreatment guidelinesCardiovascular diseaseAmerican Heart Association/American CollegeAtherosclerotic cardiovascular disease eventsBackground Limited dataIntermediate-risk participantsIntermediate-risk patientsCardiovascular disease eventsLarge prospective cohortIncremental valueNet reclassification indexStatin therapyCAC testingProspective cohortPrognostic utilityC-statisticReclassification index
2020
Intermediate and Late Outcomes With PCI vs CABG for Left Main Disease — Landmark Meta-Analysis of Randomized Trials
Akintoye E, Salih M, Olagoke O, Oseni A, Sistla P, Alqasrawi M, Panos A, Panaich S, Sellke F. Intermediate and Late Outcomes With PCI vs CABG for Left Main Disease — Landmark Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine 2020, 23: 114-118. PMID: 32921597, DOI: 10.1016/j.carrev.2020.08.040.Peer-Reviewed Original ResearchMeSH KeywordsCoronary Artery BypassCoronary Artery DiseaseHumansPercutaneous Coronary InterventionRandomized Controlled Trials as TopicStrokeTreatment OutcomeConceptsUnprotected left main diseaseLeft main diseaseEXCEL trialLate mortalityCause mortalityDirection of associationRandomized trialsLate outcomesCABGLate MIMain diseaseReasonable alternativePCITrialsSignificant differencesRCTsLower ratesHigh rateMortalityYearsLong termPatientsMixed resultsPRECOMBATStroke